Plasma protein homocysteinylation in uremia

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 12, 2007, Pages 1678-1682

  Perna, Alessandra F ^a   Acanfora, Filomena ^a   Luciano, Maria Grazia ^a   Pulzella, Paola ^a   Capasso, Rosanna ^a   Satta, Ersilia ^a   Cinzia, Lombardi ^a   Pollastro, Rosa Maria ^a   Iannelli, Simona ^a   Ingrosso, Diego ^a   De Santo, Natale G ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Albumin; Folate; Hemodialysis; Homocysteine; Protein homocysteinylation; Uremia

Indexed keywords

ALBUMIN; CYANOCOBALAMIN; DIAZEPAM; FOLIC ACID; HOMOCYSTEINE; MULTIVITAMIN; PYRIDOXINE; SALICYLIC ACID; WARFARIN;

AMINO ACID SYNTHESIS; CONFERENCE PAPER; CONTROL GROUP; DRUG EFFECT; DRUG MEGADOSE; DRUG PROTEIN BINDING; HEART INFARCTION; HEMODIALYSIS PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; IN VITRO STUDY; MALNUTRITION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEFECT; PROTEIN SYNTHESIS; STROKE; TOXICOLOGY; UREMIA;

BLOOD PROTEINS; HOMOCYSTEINE; HUMANS; RENAL DIALYSIS; UREMIA;

EID: 36849061702     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.336     Document Type: Conference Paper

References (33)

1. Perna AF, Ingrosso D, Lombardi C, Acanfora F, Satta E, Cesare CM, et al. Possible mechanisms of homocysteine toxicity. Kidney Int 2003;84:S137-40.
2. Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, De Bonis ML, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uremia. Lancet 2003;361:1693-9.
3. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999;13:2277-83.
4. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000;275:3957-62.
5. Perla-Kajan J, Twardowski T, Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids 2007;32:561-72.
6. Sengupta S, Chen H, Togawa T, DiBello PM, Majors AK, Büdy B, et al. Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem 2001;276:30111-7.
7. Jakubowski H, Goldman E. Synthesis of homocysteine thiolactone by methionyl-tRNA synthetase in cultured mammalian cells. FEBS Lett 1993;317:237-40.
8. Jacobsen DW. Homocysteine targeting of plasma proteins in hemodialysis patients. Kidney Int 2006;69:787-9.
9. Loscalzo J. Homocysteine trials - clear outcomes for complex reasons. N Engl J Med 2006;354:1629-32.
10. Ducloux D, Klein A, Kazory A, Devillard N, Chalopin J-M. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int 2006;69:331-5.
11. Skoupy S, Fodinger M, Veitl M, Perschl A, Puttinger H, Rohrer C, et al. Riboflavin is a determinant of total homocysteine plasma concentration in end-stage renal disease patients. J Am Soc Nephrol 2002;13:1331-7.
12. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004;15:442-53.
13. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004;15:420-6.
14. Suliman M, Stenvinkel P, Qureshi AR, Kalantar-Zadeh K, Barany P, Heimburger O, et al. The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant 2007;22:209-17.
15. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
16. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
17. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular disease: meta-analysis of randomized controlled trials. J Am Med Assoc 2006;296:2720-6.
18. Wang X, Gin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007;369:1876-82.
19. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H, et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006;113:1335-43.
20. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure. J Am Coll Cardiol 2006;47:1108-16.
21. Perna AF, Satta E, Acanfora F, Lombardi C, Ingrosso D, De Santo NG. Increased plasma protein homocysteinylation in hemodialysis patients. Kidney Int 2006;69:869-76.
22. Paragh G, Seres I, Balogh Z, Varga Z, Karpati I, Matyus J, et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998;80:166-70.
23. Jakubowski H. Homocysteine is a protein amino acid in humans: implications for homocysteine-linked disease. J Biol Chem 2002;277:30425-8.
24. Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr 2000;130: S377-81.
25. Uji Y, Motomiya Y, Hanyu N, Ukaji F, Okabe H. Protein-bound homocystamide measured in human plasma by HPLC. Clin Chem 2002;48:941-4.
26. Undas A, Perla J, Lacinski M, Trzeciak W, Kazmierski R, Jakubowski H. Autoantibodies against N-homocysteinylated proteins in humans: implications for atherosclerosis. Stroke 2004;35:1299-304.
27. Undas A, Jankowski M, Twardowska M, Padjas A, Jakubowski H, Szczeklik A. Antibodies to N-homocysteinylated albumin as a marker for early-onset coronary artery disease in men. Thromb Haemost 2005;93:346-50.
28. Undas A, Kolarz M, Kopec G, Glowacki R, Placzkiewicz-Jankowska E, et al. Autoantibodies against N-homocysteinylated proteins in patients on long-term haemodialysis. Nephrol Dial Transplant 2007;22:1685-9.
29. Dengler TJ, Robertz-Vaupel G-M, Dengler HJ. Albumin binding in uremia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin. Eur J Clin Pharmacol 1992;43:491-9.
30. Dockal M, Carters DC, Rüker F. The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem 1999;274:29303-10.
31. Parikh HH, McElwain K, Balasubramanian V, Leung W, Wong D, Morris ME, et al. A rapid spectrofluorimetric technique for determining drug-serum protein binding suitable for high-throughput screening. Pharmacol Res 2000;17:632-7.
32. 34 and lysine residues in human serum albumin revealed by N-homocysteinylation. J Biol Chem 2004;279:10864-71.
33. Antony AC, Tang Y-S, Khan RA, Biju MP, Xiao X, Li Q-J, et al. Translational upregulation of folate receptors is mediated by homocysteine via RNA-heterogeneous nuclear ribonucleoprotein E1 interactions. J Clin Invest 2004;113:285-301.